Drilldown: Medicines

Dexmethylphenidate (1) · Duloxetine (1) · Methylphenidate (1) · Sertraline (1)

Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Focalin, Focalin XR (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) · Zoloft (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1)

None (1) · ADHD, narcolepsy (1) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1)

None (3) · 25 mg (1)

None (3) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)

None (3) · 200 mg/d (1)

None · Oral · IV · topical · IM · intranasal · rectal · subcutaneous · Topical ophthalmic · ophthalmic · intramuscular · intravenous · transdermal · vaginal · Subcutaneous (abdomen · sublingual · thigh · Inhaled · SC · intra-articular

Other values:

Search

20–60 min (oral) (1) · 30–60 min (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)

Chronic daily dosing (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 8–12 h (1) · Long (1)

2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)

Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~22–25% (1) · ~30% (high first-pass) (1) · ~50% (highly variable) (1)

Category C (2) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

Rx-only (1) · Rx-only in US (1) · Schedule II (2)